Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Identifies "Fatal Flaws" That Block Approval Of Health Claims

This article was originally published in The Tan Sheet

Executive Summary

FDA likely will refuse new health claims applications if petitioners fail to provide relevant studies in healthy humans that evaluate the relationship between the substance and the disease, an agency official says

You may also be interested in...



Omega-3 Petition Outcome Will Reveal FDA Biomarker Stance

A citizen petition for omega-3 cardiovascular health claims is the first since the Institute of Medicine in 2010 recommended a framework to assess biomarkers for supplement health claims. The petition also will show whether FDA changed its thinking about supplement claims, says former FDA dietary supplement programs head Bill Frankos.

Omega-3 Petition Outcome Will Reveal FDA Biomarker Stance

A citizen petition for omega-3 cardiovascular health claims is the first since the Institute of Medicine in 2010 recommended a framework to assess biomarkers for supplement health claims. The petition also will show whether FDA changed its thinking about supplement claims, says former FDA dietary supplement programs head Bill Frankos.

ODS Expects Positive Impact On Industry From Promoting Supplement Science

The National Institutes of Health's Office of Dietary Supplements does not operate to promote supplement products, but shares a common interest with industry that can help spur businesses' growth - disseminating information and improving research, says ODS Director Paul Coates

Related Content

Topics

UsernamePublicRestriction

Register

PS103568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel